公开(公告)号：US20170290765A1

公开(公告)日：2017-10-12

申请号：US15512528

申请日：2015-09-17

Applicant: Epizyme, Inc.

Inventor： Edward James Olhava ,  Angelos Dovletoglou ,  Steve Wald ,  Bruce Rehlaender

IPC: A61K9/00 ,  A61K31/7076 ,  A61K47/26 ,  A61K47/02 ,  A61K47/40 ,  A61K47/12

CPC classification number: A61K9/0019 ,  A61K9/08 ,  A61K31/7076 ,  A61K47/02 ,  A61K47/12 ,  A61K47/26 ,  A61K47/40 ,  A61P35/02

Abstract: The present invention provides injectable formulations of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof and methods for treating disorders in which DOT 1-mediated protein methylation plays a part, such as cancer and neurological disorders.